BIOGEN INC. Derivative, Net Hedge Ineffectiveness Gain (Loss)
BIOGEN INC. (BIIB) reported Derivative, Net Hedge Ineffectiveness Gain (Loss) of -$4.80 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-05.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeNetHedgeIneffectivenessGainLoss · last filed 2013-02-05
- BIOGEN INC. derivative, net hedge ineffectiveness gain (loss) for the quarter ending 2012-12-31 was -$8.80M, a 1357.14% decline year-over-year.
- BIOGEN INC. derivative, net hedge ineffectiveness gain (loss) for the quarter ending 2012-09-30 was $800.00K, a 71.43% decline year-over-year.
- BIOGEN INC. derivative, net hedge ineffectiveness gain (loss) for the quarter ending 2012-06-30 was $1.30M.
- BIOGEN INC. derivative, net hedge ineffectiveness gain (loss) for the quarter ending 2012-03-31 was $1.90M, a 137.50% increase year-over-year.
- BIOGEN INC. derivative, net hedge ineffectiveness gain (loss) for fiscal 2012 was -$4.80M, a 223.08% decline from fiscal 2011.
- BIOGEN INC. derivative, net hedge ineffectiveness gain (loss) for fiscal 2011 was $3.90M.
- BIOGEN INC. derivative, net hedge ineffectiveness gain (loss) for fiscal 2010 was -$400.00K.
- BIOGEN INC. derivative, net hedge ineffectiveness gain (loss) for fiscal 2009 was -$1.10M.
| Period end | Derivative, Net Hedge Ineffectiveness Gain (Loss) 3 month | Derivative, Net Hedge Ineffectiveness Gain (Loss) 3 month as first filed | Derivative, Net Hedge Ineffectiveness Gain (Loss) 6 month | Derivative, Net Hedge Ineffectiveness Gain (Loss) 6 month as first filed | Derivative, Net Hedge Ineffectiveness Gain (Loss) 9 month | Derivative, Net Hedge Ineffectiveness Gain (Loss) 9 month as first filed | Derivative, Net Hedge Ineffectiveness Gain (Loss) 12 month | Derivative, Net Hedge Ineffectiveness Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2012-12-31 | -$8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | -$8.00M derived: sum of 2 quarters · filed 2013-02-05 | -$6.70M derived: sum of 3 quarters · filed 2013-02-05 | -$4.80M 10-K · filed 2013-02-05 | ||||
| 2012-09-30 | $800.00K 10-Q · filed 2012-10-25 | $2.10M derived: sum of 2 quarters · filed 2012-10-25 | $4.00M 10-Q · filed 2012-10-25 | $4.70M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2012-06-30 | $1.30M 10-Q · filed 2012-07-24 | $3.20M 10-Q · filed 2012-07-24 | $3.90M derived: sum of 3 quarters · filed 2013-02-05 | $6.70M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2012-03-31 | $1.90M 10-Q · filed 2012-05-01 | $2.60M derived: sum of 2 quarters · filed 2013-02-05 | $5.40M derived: sum of 3 quarters · filed 2013-02-05 | $4.20M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $3.50M derived: sum of 2 quarters · filed 2013-02-05 | $2.30M derived: sum of 3 quarters · filed 2013-02-05 | $3.90M 10-K · filed 2013-02-05 | -$3.90M 10-K · filed 2012-02-03 | |||
| 2011-09-30 | $2.80M 10-Q · filed 2012-10-25 | -$2.80M 10-Q · filed 2011-10-28 | $1.60M derived: sum of 2 quarters · filed 2012-10-25 | $3.20M 10-Q · filed 2012-10-25 | -$3.20M 10-Q · filed 2011-10-28 | $1.10M derived: sum of 4 quarters · filed 2013-02-05 | ||
| 2011-06-30 | -$1.20M 10-Q · filed 2012-07-24 | -$500.00K 10-Q · filed 2012-07-24 | -$1.70M derived: sum of 3 quarters · filed 2013-02-05 | -$300.00K derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-03-31 | $800.00K 10-Q · filed 2012-05-01 | -$500.00K derived: sum of 2 quarters · filed 2013-02-05 | $900.00K derived: sum of 3 quarters · filed 2013-02-05 | $300.00K derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2010-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $100.00K derived: sum of 2 quarters · filed 2013-02-05 | -$500.00K derived: sum of 3 quarters · filed 2013-02-05 | -$400.00K 10-K · filed 2013-02-05 | $400.00K 10-K · filed 2011-02-04 | |||
| 2010-09-30 | $1.40M 10-Q · filed 2011-10-28 | $800.00K derived: sum of 2 quarters · filed 2011-10-28 | $900.00K 10-Q · filed 2011-10-28 | -$1.10M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-06-30 | -$600.00K 10-Q · filed 2011-07-26 | $600.00K 10-Q · filed 2010-07-20 | -$500.00K 10-Q · filed 2011-07-26 | $500.00K 10-Q · filed 2010-07-20 | -$2.50M derived: sum of 3 quarters · filed 2012-02-03 | -$2.40M derived: sum of 4 quarters · filed 2012-02-03 | ||
| 2010-03-31 | $100.00K 10-Q · filed 2011-04-21 | -$1.90M derived: sum of 2 quarters · filed 2012-02-03 | -$1.80M derived: sum of 3 quarters · filed 2012-02-03 | -$100.00K derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2009-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | -$1.90M derived: sum of 2 quarters · filed 2012-02-03 | -$200.00K derived: sum of 3 quarters · filed 2012-02-03 | -$1.10M 10-K · filed 2012-02-03 | ||||
| 2009-09-30 | $100.00K 10-Q · filed 2010-10-26 | $1.80M derived: sum of 2 quarters · filed 2010-10-26 | $900.00K 10-Q · filed 2010-10-26 | |||||
| 2009-06-30 | $1.70M 10-Q · filed 2010-07-20 | $800.00K 10-Q · filed 2010-07-20 | ||||||
| 2008-12-31 | -$200.00K 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |